Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on July 11, 2013. These acquisitions were executed at a price of 1,752.133 pence per share through the reinvestment of dividends under the GlaxoSmithKline ShareReward Plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is a regulatory notification compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Dividend reinvestment via the ShareReward Plan.
- Transaction Date: July 11, 2013.
- Share Price: 1,752.133 pence per Ordinary Share.
- Participants: Includes Sir Andrew Witty (23 shares), Mr. S M Bicknell (35 shares), Mr. D S Redfern (35 shares), Ms. C Thomas (35 shares), and others.
- Notification Date: July 12, 2013.